Epiphany

epic oncology™

 
epic oncology™
Available Analyses
THIS HAS TO CHANGE!!!!
Epiphany’s detailed statistics are provided in Analyses. Analyses are grouped by the type of output from Epiphany’s flow model. As client needs change, the type, depth, and definition of key analyses may also change. Epiphany is constantly assessing the need to deepen, redefine, or modify the available analyses.

The following is a detailed list of the data available for all countries in the epic oncology™ database. Please note that not all analyses will be provided for each cancer type; analyses are defined based on current treatment modalities and approaches (e.g., radiotherapy, transplantation, ablative treatments, maintenance, hormone therapy).

Incidence  Estimates of newly diagnosed patients each year, by stage/subset, gender, and age-group. 
No Access (Incidence) Estimate of incident patients who do NOT have access to cancer care. Provided for a limited number of countries where access is an issue. These patients are removed from more advanced statistics.
Prevalence by Stage 5-, 10-, and 15-year prevalence estimates by stage and/or subset. Provides an estimate of the total number of patients who are alive, but not all may be seeking care (some may be in remission). 
Available Populations Epiphany’s estimate of patients who might actively be seeking care. Excludes patients in remission, but allows for subsets of incidence/newly metastatic, relapsed and refractory, and no therapy patients.
Uniquely Treated Patients Estimate of the actual number of patients being treated in a given year. Patients who may be treated more than once are ONLY counted during their first treatment. These estimates are provided for all treatments, drug therapy, and hormone therapy. These estimates include those in chronic/long-term treatment.
Total Treated Populations Estimates of the total treatment opportunities in a given year, focused on short-term (acute) treatments (excludes those in chronic care). These are considered a population and not patients since this statistic allows for multiple counts of a single patient who is treated more than once in a single year.
Populations by Modality Estimates of treated patients by specific modalities: surgery, radiotherapy, transplantation, ablative/local therapies, drug therapies (all drugs except hormone therapy), and hormone therapy.
Adjuvant/Neoadjuvant Estimates of adjuvant and neoadjuvant therapy in the front-line (first course) setting. This is provided for chemotherapy (drug therapy), chemoradiotherapy, and/or hormone therapy.
Chemotherapy Subsets
Estimates of patients in key treatment subsets including induction, consolidation, radiochemotherapy, and local chemotherapy (topicals, TACE, HAI, etc.). 
Chronic Therapy Estimates of patients on chronic therapy each year. Epiphany calculates these patients as new starts (initiated care during the year) and total on therapy at year-end (number of patients estimated to move to the next year on chronic therapy). Chronic therapy is comprised of both maintenance drug therapy and long-term hormone therapy.
Special Populations
For specific cancers, Epiphany provides additional details considered “special populations.” These include castrate-resistant prostate cancer (separated into asymptomatic and symptomatic), transformed lymphoma (indolent B-cell NHL transforming to aggressive DLBCL), and platinum status ovarian cancer (sensitive, refractory, and resistant– Platinum-free interval of 0 to 6 months and 6 to 12 months).
Biomarkers Biomarkers are available for some cancers. The following is a list of biomarkers currently included in the 2012 dataset: ALK, BRAF, BRCA1/2, CEBPA, dMMR (MSI), EGFR Mutation, EGFR Copy Number, FLT3-ITD, HER2 overexpression, Hormone status, KRAS, NPM1, NRAS, PTEN. Epiphany is continuously assessing new biomarkers for inclusion in the data set; if you are interested in a particular biomarker that is not listed, please contact our Epidemiology Team.
Treatment Failures
Estimates of patients failing drug or hormone therapy during the year.
Standard Prevalence 5-, 10-, and 15-year standard prevalence estimates provided by gender and age-group, but not by stage and generated using overall average survival. 
Mortality
Estimate of the number of patients who died during the year, divided into groups of “died from” their cancer or “died with” their cancer (died of another non-cancer related cause). 
Epiphany Partners, Inc.
1900 South Norfolk Street, Suite 260
San Mateo, California 94403
Main 650-242-4626
Fax 650-288-0036
info@time4epi.com 
Driving Directions
Follow us: LinkedIn
©2013 Copyright Epiphany Partners, Inc.  •  Terms of Use  •  Privacy Policy  •  Site Map